The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process
Mehul Bhattacharyya, Larry E. Miller, Anna L. Miller, Ruemon Bhattacharyya
Topics & Concepts
Duchenne muscular dystrophyMedicineMuscular dystrophyDrug approvalPharmacologyInternal medicineDrugMuscle Physiology and DisordersProsthetics and Rehabilitation RoboticsMuscle activation and electromyography studies